tasimelteon · Hetlioz

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Non-24-Hour Sleep-Wake Disorder

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
US
  • Nighttime Sleep Disturbances in Smith-Magenis Syndrome (SMS) HETLIOZ capsules are indicated for the treatment of nighttime sleep disturbances in SMS in patients 16 years of age and older. HETLIOZ LQ oral suspension is indicated for the treatment of nighttime sleep disturbances in SMS in pediatric patients 3 to 15 years of age.
Product first approved 2014Outside this platform's coverageFDA label
EU
  • Non-24-Hour Sleep-Wake Disorder in totally blind adults
Product first approved 2015EMA

Company guidance: data expected in 2026 (Vanda Pharmaceuticals, 6 Aug 2026). “◦ The Phase III study of HETLIOZ ® in the treatment of delayed sleep phase disorder (DSPD) with results expected in 2026.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (11)
Non-24-Hour Sleep-Wake Disorder
Other / comorbidity
NCT06953869 · Vanda Pharmaceuticals
2025-04-21 – 2028-01 · Insomnia Disorder
What this study did
NCT04652882 · Vanda Pharmaceuticals
2020-12-09 – 2026-09-04 · Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm, Chronobiology Disorders
What this study did
NCT05361707 · Vanda Pharmaceuticals
2021-07-28 – 2025-07 · Autism Spectrum Disorder, Sleep Disorder, Neurological Disorder, Sleep Disturbance
What this study did
NCT06701396 · Vanda Pharmaceuticals
2024-10-08 – 2025-06-30 · Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm, Chronobiology Disorders, Gene Mutations and Other Alterations Nec
What this study did
NCT03373201 · Vanda Pharmaceuticals
2017-10-16 – 2018-03-05 · Jet Lag Type Insomnia
What this study did
NCT00548340 · Vanda Pharmaceuticals
2007-11 – 2008-06 · Primary Insomnia
What this study did
NCT00291187 · Vanda Pharmaceuticals
2006-02 – 2006-08 · Insomnia
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT02231008 · Vanda Pharmaceuticals
2015-09 – 2022-01 · Smith-Magenis Syndrome, Circadian
What this study did
NCT01428661 · Vanda Pharmaceuticals
2011-09 – 2013-05 · Major Depressive Disorder
What this study did
Phase 2 (2)
Other / comorbidity
NCT03291041 · Vanda Pharmaceuticals
2016-07 – 2017-11 · Jet Lag Disorder
What this study did
NCT00490945 · Vanda Pharmaceuticals
2004-07 – 2005-03 · Circadian Rhythm Sleep Disorders
What this study did
Phase 1 (11)
Non-24-Hour Sleep-Wake Disorder
NCT02776215 · Vanda Pharmaceuticals
2016-10-04 – 2017-12-20 · Circadian Rhythm Sleep Disorders, Non-24 Hour Sleep-Wake Disorder, Autism Spectrum Disorder, Smith-Magenis Syndrome
What this study did
Other / comorbidity
NCT05922995 · Brigham and Women's Hospital
2023-09-30 – 2023-12-01 · REM Behavior Disorder
What this study did
NCT05572281 · Vanda Pharmaceuticals
2022-05-18 – 2022-06-15 · Healthy
What this study did
NCT06323655 · Vanda Pharmaceuticals
2018-07-19 – 2018-08-28 · Healthy Volunteers
What this study did
NCT01637636 · Vanda Pharmaceuticals
2012-06 – 2012-08 · Healthy
What this study did
NCT01578057 · Vanda Pharmaceuticals
2012-04 – 2012-06 · Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With Ethanol
What this study did
NCT01526746 · Vanda Pharmaceuticals
2012-02 – 2012-06 · Renal Impairment
What this study did
NCT01540500 · Vanda Pharmaceuticals
2012-02 – 2012-03 · Healthy Volunteers
What this study did
NCT01477619 · Vanda Pharmaceuticals
2011-11 – 2012-01 · Healthy Volunteers
What this study did
NCT01402076 · Vanda Pharmaceuticals
2011-08 – 2011-08 · Healthy Volunteers
What this study did
NCT01271387 · Vanda Pharmaceuticals
2011-01 – 2011-08 · Hepatic Impairment
What this study did
Phase 4 (1)
Non-24-Hour Sleep-Wake Disorder
NCT02130999 · Vanda Pharmaceuticals
2014-05 – 2014-05 · Non-24-Hour-Sleep-Wake Disorder
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tasimelteon (Hetlioz): this drugApprovedSmall moleculeMelatonin receptor (MT1/MT2)Partial signal
NCT01430754: RESET randomized withdrawal: maintenance of entrainment, continued tasimelteon vs withdrawal to placebo: 9/10 (90%) vs 2/10 (20%), difference 70% (95% CI 26.4 to 100.0), p=0.0026 (Lockley et al., Lancet 2015).
Melatonin Prolonged-Release (Circadin)
Phase 3(overall)
—Melatonin receptor (MT1/MT2)not yet graded
NCT01906866: Total Sleep Time (TST) (13 weeks): Circadin 2/5/10 mg 51.03 minutes (95% CI 30.3 to 71.76) vs Placebo 18.71 minutes (95% CI -2.73 to 40.15)

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Hetlioz (tasimelteon) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
November 2027 (1)
Phase 3Insomnia DisorderRecruiting
Est. primary completion 2027-11 · NCT06953869 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

29 September 2026Topline resultPhase III study in DSWPD met its primary endpoint
Vanda Pharmaceuticals Inc. · Source ↗
3 June 2026Complete response letterFDA grants Vanda hearing request on proposal to refuse approval of HETLIOZ sNDA
US, FDA · FDA · Source ↗
7 January 2026Complete response letterFDA says HETLIOZ jet lag sNDA cannot be approved
US, FDA · Source ↗